These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24996374)

  • 1. Clinical pharmacology of deferasirox.
    Tanaka C
    Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M; Plosker GL
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Chirnomas D; Smith AL; Braunstein J; Finkelstein Y; Pereira L; Bergmann AK; Grant FD; Paley C; Shannon M; Neufeld EJ
    Blood; 2009 Nov; 114(19):4009-13. PubMed ID: 19724055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K; Ohyashiki K; Urabe A; Hata T; Nakao S; Ozawa K; Ishikawa T; Kato J; Tatsumi Y; Mori H; Kondo M; Taniguchi J; Tanii H; Rojkjaer L; Omine M
    Int J Hematol; 2008 Jul; 88(1):73-81. PubMed ID: 18597054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
    Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
    Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICL670A: preclinical profile.
    Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
    Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
    [No Abstract]   [Full Text] [Related]  

  • 8. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
    Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
    Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
    Bruin GJ; Faller T; Wiegand H; Schweitzer A; Nick H; Schneider J; Boernsen KO; Waldmeier F
    Drug Metab Dispos; 2008 Dec; 36(12):2523-38. PubMed ID: 18775980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP; Keam SJ; Keating GM
    Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
    Galanello R; Piga A; Cappellini MD; Forni GL; Zappu A; Origa R; Dutreix C; Belleli R; Ford JM; Rivière GJ; Balez S; Alberti D; Séchaud R
    J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F; Puntoni M; Marini V; Fucile C; Milano G; Robbiano L; Perrotta S; Pinto V; Martelli A; Forni GL
    Eur J Haematol; 2015 Apr; 94(4):310-7. PubMed ID: 25081908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of tridentate iron chelators: from desferrithiocin to ICL670.
    Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
    Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
    Séchaud R; Dutreix C; Balez S; Pommier F; Dumortier T; Morisson S; Brun E
    Int J Clin Pharmacol Ther; 2008 Feb; 46(2):102-8. PubMed ID: 18218291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
    Sechaud R; Robeva A; Belleli R; Balez S
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.